{"id":781166,"date":"2023-08-30T17:23:00","date_gmt":"2023-08-30T21:23:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/"},"modified":"2023-08-30T17:23:00","modified_gmt":"2023-08-30T21:23:00","slug":"oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/","title":{"rendered":"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO and SAN DIEGO, Aug.  30, 2023  (GLOBE NEWSWIRE) &#8212; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in the first half of September:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Citi\u2019s 2023 18<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual BioPharma Conference<\/strong> \u2013 Participating in a targeted oncology panel on Wednesday, September 6, 2023, at 1:00 p.m. ET <\/p>\n<\/li>\n<li>\n          <strong>Wells Fargo 2023 Healthcare Conference<\/strong> \u2013 Participating in a fireside chat on Thursday, September 7, 2023, at 11:00 a.m. ET <\/p>\n<\/li>\n<li>\n          <strong>H.C. Wainwright 25<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Global Investment Conference \u2013 <\/strong>Presenting company overview on Monday, September 11, 2023, at 12:30 p.m. ET <\/p>\n<\/li>\n<li>\n          <strong>Baird 2023 Global Healthcare Conference<\/strong> \u2013 Participating in a fireside chat on Tuesday, September 12, 2023, at 2:35 p.m. ET<\/li>\n<\/ul>\n<p>Webcasts of the panel discussion and presentations will be available through the investor section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0bcN9a52THm_lP4WSFaMmvQregHVr78algdafaugKJ8QXSi0wnMqdRSnKf-jFXruWnLnZ6_PFo7kVUZfoxg9m_U9hoJySiUWDB5K3oKWUZQ=\" rel=\"nofollow noopener\" target=\"_blank\">www.oricpharma.com<\/a>. Replays of webcasts will be available for 90 days following the events.<\/p>\n<p align=\"justify\">\n        <strong>About ORIC Pharmaceuticals, Inc. <\/strong>\n      <\/p>\n<p align=\"justify\">ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by\u00a0<em>Overcoming\u00a0Resistance\u00a0In\u00a0Cancer.\u00a0<\/em>ORIC\u2019s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0bcN9a52THm_lP4WSFaMmnYApeMS8XmgQjkJ9fhFti-XVS4FXRTAani5i_92fmJsFGO0UyU38mGIcFFhrG4RNotTF64auH1JXcxm3ENluU84dESJC6GsiPUZwozkQvhlDEpQjpomjPjwEnY0tL0gRao_Hx_Rv4BqNn999RVnMYAFuVoi0nj5gI5qKGp3VH5Ll3llDUYPHX3Wb-A0YfHcsH2eSxycIOB-YQC0tzSKM5kjyEKMTz7554ANI-jHjUnKQxp9sAVNmQeFhinmJEJOwQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.oricpharma.com<\/u><\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v3DZe83pFSjQt3BlnbzEZYTqNhO_BDmUiHfSVRtntmjPhpeB3SY7tMrOQ5K3H_9E8QaqJPTghGnO4rBRM65zjBpCE8Kk87SsqXUk-mNS_KJUT59hqBO8a_88pDL21UfDQkWN36q7hwYUNj7G0kKEwC48WrgseHGlAtIYjbTANSZx0oogyHRKoG_Ivz-FPn6bvB9LGQ5sk_WRNWm3ev6i2oVjF9vkXSpoqAkP8N8-oJw=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Twitter<\/u><\/a><u>\u00a0<\/u>or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qzmS0iZFoUSehpftz7jVBNO8YEWJ69id6fF8J_C9M6xDkezR19qKvj66Rv6hDIkPdn_zEqprEdw5RTinEBfmee0yB_jyi1yhUqhdweOO9kc54da0e5hrpJdf7wEmkEwoLY5n5YrQ6r5SZVonsPkbaiY2EYgxfCEBBTuUALxeJGi3YFvu-7jhnmwymLLG4982kAQTfcOORp_TlW5l5EnU7kzw6dVUBYqcQRSQUC4J3bB2fdoWTLaT4ZFskDd_4cidpKhJrL6QLhN52qRBZBtuZw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Dominic Piscitelli, Chief Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xXj5rLWptb22cY5dlEqlzcsj0VpHhMYUfzzpcaEgcOzGTGYN5AeOuvZaPOFm9qNsPR7YebAh8oC0b6vd8saVuvhTsjSnXqn76cJrNJ9m8MtXqftSRWrB2XD1XOJ_YfmJOu60vkfq_Sedy5BNAndvBw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>dominic.piscitelli@oricpharma.com<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7tlqVeaXka4a0-KyPWl7tSNSBLXuAvIPxnHMwvuUfqig41jvd1k_JETLj6qPfJTBj7z-2xlCdOg3iJjhTP-9CDQITkarf1agLmki6NuTt5M=\" rel=\"nofollow noopener\" target=\"_blank\"><u>info@oricpharma.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Mjk3YmI2NTMtZWVmNS00ZWYyLTg1ODYtOTY0N2FiNThkZmNlLTEwOTI0NTY=\/tiny\/ORIC-Pharmaceuticals.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in the first half of September: Citi\u2019s 2023 18 th Annual BioPharma Conference \u2013 Participating in a targeted oncology panel on Wednesday, September 6, 2023, at 1:00 p.m. ET Wells Fargo 2023 Healthcare Conference \u2013 Participating in a fireside chat on Thursday, September 7, 2023, at 11:00 a.m. ET H.C. Wainwright 25 th Annual Global Investment Conference \u2013 Presenting company overview on Monday, September 11, 2023, at 12:30 p.m. ET Baird 2023 Global Healthcare Conference \u2013 Participating &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781166","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in the first half of September: Citi\u2019s 2023 18 th Annual BioPharma Conference \u2013 Participating in a targeted oncology panel on Wednesday, September 6, 2023, at 1:00 p.m. ET Wells Fargo 2023 Healthcare Conference \u2013 Participating in a fireside chat on Thursday, September 7, 2023, at 11:00 a.m. ET H.C. Wainwright 25 th Annual Global Investment Conference \u2013 Presenting company overview on Monday, September 11, 2023, at 12:30 p.m. ET Baird 2023 Global Healthcare Conference \u2013 Participating &hellip; Continue reading &quot;ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T21:23:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2023-08-30T21:23:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/\"},\"wordCount\":326,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/\",\"name\":\"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=\",\"datePublished\":\"2023-08-30T21:23:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/","og_locale":"en_US","og_type":"article","og_title":"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in the first half of September: Citi\u2019s 2023 18 th Annual BioPharma Conference \u2013 Participating in a targeted oncology panel on Wednesday, September 6, 2023, at 1:00 p.m. ET Wells Fargo 2023 Healthcare Conference \u2013 Participating in a fireside chat on Thursday, September 7, 2023, at 11:00 a.m. ET H.C. Wainwright 25 th Annual Global Investment Conference \u2013 Presenting company overview on Monday, September 11, 2023, at 12:30 p.m. ET Baird 2023 Global Healthcare Conference \u2013 Participating &hellip; Continue reading \"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T21:23:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences","datePublished":"2023-08-30T21:23:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/"},"wordCount":326,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/","name":"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=","datePublished":"2023-08-30T21:23:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzAyNCM1Nzg2NjUwIzIwODA4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781166"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781166\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}